CA2370769A1 - Administration regulee de bisphosphonates - Google Patents

Administration regulee de bisphosphonates Download PDF

Info

Publication number
CA2370769A1
CA2370769A1 CA002370769A CA2370769A CA2370769A1 CA 2370769 A1 CA2370769 A1 CA 2370769A1 CA 002370769 A CA002370769 A CA 002370769A CA 2370769 A CA2370769 A CA 2370769A CA 2370769 A1 CA2370769 A1 CA 2370769A1
Authority
CA
Canada
Prior art keywords
delivery device
drug delivery
bisphosphonates
bisphosphonate
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002370769A
Other languages
English (en)
Inventor
Petr Kuzma
Agis Kydonieus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HYDROMED SCIENCES A DIVISION OF GP STRATEGIES Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2370769A1 publication Critical patent/CA2370769A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur un procédé d'administration régulée de bisphosphonates dans le traitement de l'ostéoporose, la maladie de Paget et autres maladies osseuses. Ce procédé consiste à utiliser un dispositif implantable pour administrer des quantités efficaces, d'un point de vue pharmaceutique, de bisphosphonate, sans manifestation de nombreux effets secondaires associés à l'administration par voie orale.
CA002370769A 1999-04-22 2000-04-19 Administration regulee de bisphosphonates Abandoned CA2370769A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13072899P 1999-04-22 1999-04-22
US60/130,728 1999-04-22
PCT/US2000/010696 WO2000064516A1 (fr) 1999-04-22 2000-04-19 Administration regulee de bisphosphonates

Publications (1)

Publication Number Publication Date
CA2370769A1 true CA2370769A1 (fr) 2000-11-02

Family

ID=22446043

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002370769A Abandoned CA2370769A1 (fr) 1999-04-22 2000-04-19 Administration regulee de bisphosphonates

Country Status (4)

Country Link
EP (1) EP1210138A4 (fr)
AU (1) AU4652100A (fr)
CA (1) CA2370769A1 (fr)
WO (1) WO2000064516A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984400B2 (en) 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
IL125336A0 (en) 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US7008645B2 (en) 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
FR2803521B1 (fr) * 2000-01-12 2002-10-25 Ceva Sante Animale Utilisation de l'acide tiludronique et de ses derives chez la volaille pour la preparation d'un medicament destine a prevenir et a traiter l'osteoporose
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
EP1365770A2 (fr) * 2001-02-07 2003-12-03 Durect Corporation Dispositifs et methodes de gestion de la densite osseuse
KR20020080018A (ko) * 2001-04-10 2002-10-23 한국화학연구원 비스포스포네이트 골 흡수억제제의 이식형 서방성제제
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
FI20031120A0 (fi) * 2003-07-31 2003-07-31 Bci Bioabsorbable Concepts Ltd Monifunktionaalinen implanttilaite
ES2561463T3 (es) * 2003-08-21 2016-02-26 Addbio Ab Dispositivo de implante recubierto con bisfosfonato y método para el mismo
US20100247607A1 (en) * 2009-03-26 2010-09-30 Psivida Us, Inc. Implantable formulations of bisphosphonic acids
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CA2769633C (fr) 2009-07-31 2017-06-06 Thar Pharmaceuticals, Inc. Procede de cristallisation et biodisponibilite
US20130064861A1 (en) * 2010-02-17 2013-03-14 Zvi Schwartz Compositions and methods for modifying in vivo calcification of hydrogels
WO2012071517A2 (fr) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Nouvelles formes cristallines
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
JO3394B1 (ar) * 2014-07-04 2019-10-20 Osteo Pharma B V تركيبات ومنتجات للاستعمال في علاج كسور وعيوب العظام
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
US20210205459A1 (en) * 2018-06-01 2021-07-08 The University Of North Carolina At Chapel Hill Injectable thermoresponsive hydrogels as a combinatory modality for controlled drug delivery, biomaterial implant and 3d printing bioink

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753652A (en) * 1984-05-04 1988-06-28 Children's Medical Center Corporation Biomaterial implants which resist calcification
US5196409A (en) * 1989-08-20 1993-03-23 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Bisphosphonates, pharmaceutical compositions, and process for the treatment of irregularities in calcium metabolism
CA2151240A1 (fr) * 1992-12-23 1994-07-07 Donna T. Whiteford Administration de biophosphonate et d'oestrogene pour le traitement et la prevention de la perte osseuse
FI92465C (fi) * 1993-04-14 1994-11-25 Risto Tapani Lehtinen Menetelmä endo-osteaalisten materiaalien käsittelemiseksi
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
JP3476930B2 (ja) * 1994-11-16 2003-12-10 オリンパス株式会社 生体埋入部材
AU5973496A (en) * 1995-06-06 1996-12-24 Merck & Co., Inc. Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
US5898038A (en) * 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis

Also Published As

Publication number Publication date
AU4652100A (en) 2000-11-10
EP1210138A1 (fr) 2002-06-05
EP1210138A4 (fr) 2003-05-07
WO2000064516A1 (fr) 2000-11-02

Similar Documents

Publication Publication Date Title
CA2370769A1 (fr) Administration regulee de bisphosphonates
RU2297229C2 (ru) Фармацевтическое применение бисфосфонатов
CA2407747C (fr) Composition pharmaceutique de type gel pour administration sous-cutanee contenant des acides biphosphoniques ou leurs sels
ES2253919T3 (es) Composiciones que contienen acidos difosfonicos.
KR100864743B1 (ko) 비스포스포네이트의 투여 방법
AU693541B2 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
AU2002257802A1 (en) Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
KR100391732B1 (ko) 골 흡수 억제를 위한 조성물
JP2004501104A (ja) 骨代謝疾患の処置のための医薬の製造のための、ゾレドロネートの使用
US20060233724A1 (en) Medicinal composition for peridontal pocket administration containing bisphosphonic acid derivative or its salt as the active ingredient
UA67748C2 (uk) Активний інгредієнт для виробництва лікарського засобу для інгібування резорбції кісткової тканини у людини (варіанти)
MXPA01003435A (en) Compositions containing diphosphonic acids
MXPA96005327A (en) Use of certain derivatives of acidometanisphisphonic to prevent the loosening of protesis and the emigration of proteins

Legal Events

Date Code Title Description
FZDE Discontinued